The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion
Open accessAbstract
A recently approved peptidic human immunodeficiency virus type 1 (HIV-1) fusion inhibitor, T-20 (Fuzeon; Trimeris Inc.), has shown significant promise in clinical application for treating HIV-1-infected individuals who have failed to respond to the currently available antiretroviral drugs. However, T-20 must be injected twice daily and is too expensive. Therefore, it is essential to develop orally available small molecule HIV-1 fusion inhibitors. By screening a chemical library consisting of “drug-like” compounds, we identified two N-substituted pyrroles, designated NB-2 and NB-64, that inhibited HIV-1 replication at a low micromolar range. The absence of the COOH group in NB-2 and NB-64 resulted in a loss of anti-HIV-1 activity, suggesting that this acid group plays an important role in mediating the antiviral activity. NB-2 and NB-64 inhibited HIV-1 fusion and entry by interfering with the gp41 six-helix bundle formation and disrupting the α-helical conformation. They blocked a d- peptide binding to the hydrophobic pocket on surface of the gp41 internal trimeric coiled-coil domain. Computer-aided molecular docking analysis has shown that they fit inside the hydrophobic pocket and that their COOH group interacts with a positively charged residue (K574) around the pocket to form a salt bridge. These results suggest that NB-2 and NB-64 may bind to the gp41 hydrophobic pocket through hydrophobic and ionic interactions and block the formation of the fusion-active gp41 core, thereby inhibiting HIV-1-mediated membrane fusion and virus entry. Therefore, NB-2 and NB-64 can be used as lead compounds toward designing and developing more potent small molecule HIV-1 fusion inhibitors targeting gp41.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 3×
“The percent inhibition by the compounds was calculated as previously described (22) and the effective con- centration for 50% inhibition (EC50) was calculated by using the software Calcusyn (6), kindly provided by T. C. Chou (Sloan-Kettering Cancer Center, New York, N.Y.).”
MethodCore Structure of gp41 from the HIV Envelope Glycoprotein
Chan, D. C., Fass, D., Berger, J. M., & Kim, P. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80205-6 · Cited by 1,959
Atomic structure of the ectodomain from HIV-1 gp41
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., & Wiley, D. C. (1997) · Nature · doi:10.1038/387426a0 · Cited by 1,622
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569 · cited 1×
“However, the future application of T-20 may be constrained due to its lack of oral availability, the high cost of production, and the rapid emergence of resistant HIV-1 strains in patients receiving T-20 ( 50 ).”
BackgroundChan, D. C., & Kim, P. S. (1998) · Cell · doi:10.1016/s0092-8674(00)81430-0 · Cited by 1,277
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., & Matthews, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9770 · Cited by 931
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751
A trimeric structural domain of the HIV-1 transmembrane glycoprotein
Lu, M., Blacklow, S. C., & Kim, P. S. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb1295-1075 · Cited by 701
Sattentau, Q. J., & Moore, J. P. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.2.407 · Cited by 600
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554
Atomic structure of a thermostable subdomain of HIV-1 gp41
Tan, K., Liu, J.-H., Wang, J.-H., Shen, S., & Lu, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12303 · Cited by 532
Jiang, S., Lin, K., Strick, N., & Neurath, A. R. (1993) · Nature · doi:10.1038/365113a0 · Cited by 508
Self-citationWild, C., Oas, T., McDanal, C., Bolognesi, D., & Matthews, T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10537 · Cited by 485
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
Chan, D. C., Chutkowski, C. T., & Kim, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15613 · Cited by 477
Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A., & Kim, P. S. (1999) · Cell · doi:10.1016/s0092-8674(00)80066-5 · Cited by 442
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, R., Yamanaka, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832214100 · Cited by 357
Mittal, A., & Bentz, J. (2004) · The Structure of Biological Membranes, Second Edition · doi:10.1201/9781420040203.ch16 · Cited by 301
Twenty years of therapy for HIV-1 infection
Pomerantz, R. J., & Horn, D. L. (2003) · Nature Medicine · doi:10.1038/nm0703-867 · Cited by 284
Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress
Toogood, P. L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010468s · Cited by 281
Novel Therapies Based on Mechanisms of HIV-1 Cell Entry
Kilby, J. M., & Eron, J. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022812 · Cited by 254
Si, Z., Madani, N., Cox, J. M., Chruma, J. J., Klein, J. C., Schön, A., Phan, N., Wang, L., Biorn, A. C., Cocklin, S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307953101 · Cited by 247
HIV and AIDS: 20 years of science
Fauci, A. S. (2003) · Nature Medicine · doi:10.1038/nm0703-839 · Cited by 243
Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4
Schols, D., Esté, J. A., Henson, G., & De Clercq, E. (1997) · Antiviral Research · doi:10.1016/s0166-3542(97)00025-9 · Cited by 220
Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., et al. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760072294 · Cited by 198
McKnight, A., Wilkinson, D., Simmons, G., Talbot, S., Picard, L., Ahuja, M., Marsh, M., Hoxie, J. A., & Clapham, P. R. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1692-1696.1997 · Cited by 173
Ernst, J. T., Kutzki, O., Debnath, A. K., Jiang, S., Lu, H., & Hamilton, A. D. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020118)41:2<278::aid-anie278>3.0.co;2-a · Cited by 172
Self-citationChen, C. H., Matthews, T. J., McDanal, C. B., Bolognesi, D. P., & Greenberg, M. L. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3771-3777.1995 · Cited by 169
Debnath, A. K., Radigan, L., & Jiang, S. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990154t · Cited by 163
Self-citationJiang, S., Kang, L., & Lu, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10213-10217.1998 · Cited by 153
Self-citationA Trimeric Structural Subdomain of the HIV-1 Transmembrane Glycoprotein
Lu, M., & Kim, P. S. (1997) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.1997.10508958 · Cited by 150
Protein–protein interfaces: mimics and inhibitors
Cochran, A. G. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(01)00262-9 · Cited by 149
Small molecule antagonists of proteins
Gadek, T. R., & Nicholas, J. B. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01479-x · Cited by 120
FOUTS, T. R., Tuskan, R. G., Godfrey, K., Reitz, M. S., Hone, D. M., Lewis, G. K., & DeVico, A. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.24.11427-11436.2000 · Cited by 115
Bovine β–lactoglobulin modified by 3–hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV
NEURATH, A. R., Jiang, S., Strick, N., Kang, L., Li, Y., & Debnath, A. K. (1996) · Nature Medicine · doi:10.1038/nm0296-230 · Cited by 78
Self-citationJiang, S., Lin, K., & NEURATH, A. R. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.174.6.1557 · Cited by 77
Self-citationDwyer, J. J., Hasan, A. N., Wilson, K. L., White, J. M., Matthews, T. J., & Delmedico, M. K. (2003) · Biochemistry · doi:10.1021/bi027283n · Cited by 60
Inhibitors of protein-protein interactions
Gadek, T. R., & Ockey, D. A. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.3.393 · Cited by 21
Zhao, Q., Lü, H., Schols, D., Clercq, E. D., & Jiang, S. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203322588297 · Cited by 13
Self-citation
Cited by
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
Lu, L., Liu, Q., Zhu, Y., Chan, K.-H., Qin, L., Li, Y., Wang, Q., Chan, J. F.-W., Du, L., Yu, F., et al. (2014) · Nature Communications · doi:10.1038/ncomms4067 · Cited by 388
Self-citationVan den Bergh, R., Morin, S., Sass, H. J., Grzesiek, S., Vekemans, M., Florence, E., Thanh Thi Tran, H., Imiru, R. G., Heyndrickx, L., Vanham, G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035074 · Cited by 40
“For time of addition experiments, the MT-2 setup published elsewhere was used [25].”
Method
Metadata
- Authors
- Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., & Debnath, A. K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-11
- Volume
- 48
- Issue
- 11
- Pages
- 4349-4359
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2043448829
- Cited by
- 264
- References
- 41
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.